Business Description
Poseida Therapeutics Inc
NAICS : 325412
SIC : 2833
ISIN : US73730P1084
Share Class Description:
PSTX: Ordinary SharesDescription
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.35 | |||||
| Equity-to-Asset | 0.32 | |||||
| Debt-to-Equity | 1 | |||||
| Debt-to-EBITDA | -0.9 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -2.65 | |||||
| Beneish M-Score | -2.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 29.4 | |||||
| 3-Year EPS without NRI Growth Rate | 27.6 | |||||
| 3-Year FCF Growth Rate | 33.7 | |||||
| 3-Year Book Growth Rate | -36.5 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.21 | |||||
| 9-Day RSI | 61.75 | |||||
| 14-Day RSI | 57.1 | |||||
| 6-1 Month Momentum % | -11.01 | |||||
| 12-1 Month Momentum % | 69.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.56 | |||||
| Quick Ratio | 2.56 | |||||
| Cash Ratio | 2.34 | |||||
| Days Sales Outstanding | 44.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.6 | |||||
| Shareholder Yield % | -3.61 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -138.86 | |||||
| Net Margin % | -131.95 | |||||
| FCF Margin % | -86.92 | |||||
| ROE % | -89.99 | |||||
| ROA % | -37.97 | |||||
| ROIC % | -123.82 | |||||
| ROC (Joel Greenblatt) % | -233.65 | |||||
| ROCE % | -45.31 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.25 | |||||
| PB Ratio | 3.47 | |||||
| Price-to-Tangible-Book | 3.68 | |||||
| EV-to-EBIT | -1.69 | |||||
| EV-to-EBITDA | -1.79 | |||||
| EV-to-Revenue | 2.05 | |||||
| EV-to-Forward-Revenue | 2.43 | |||||
| EV-to-FCF | -2.48 | |||||
| Price-to-Net-Current-Asset-Value | 7.55 | |||||
| Price-to-Net-Cash | 14.38 | |||||
| Earnings Yield (Greenblatt) % | -59.17 | |||||
| FCF Yield % | -24.49 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers